Abatacept could delay rheumatoid arthritis for high-risk patients

One year of treatment with biologic drug abatacept (Orencia; Bristol Myers Squibb) delays progression to rheumatoid arthritis (RA) for up to four years in high-risk patients, according to the results of a study. The results of the randomised, double-blind, placebo-controlled trial, published in The Lancet Rheumatology on 20 January 2026, build on an earlier study — […]